X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (89) 89
Book / eBook (32) 32
Publication (12) 12
Newspaper Article (5) 5
Book Review (4) 4
Conference Proceeding (4) 4
Book Chapter (3) 3
Magazine Article (1) 1
Trade Publication Article (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (52) 52
humans (51) 51
female (39) 39
male (36) 36
middle aged (33) 33
aged (28) 28
abridged index medicus (21) 21
adult (18) 18
aged, 80 and over (14) 14
treatment outcome (14) 14
mortality (11) 11
ophthalmology (11) 11
exhibitions (10) 10
prognosis (10) 10
article (9) 9
clinical trials (9) 9
diabetes (9) 9
health aspects (9) 9
care and treatment (8) 8
drug therapy (8) 8
follow-up studies (8) 8
oncology (8) 8
research (8) 8
united states (8) 8
analysis (7) 7
antibodies, monoclonal - therapeutic use (7) 7
art (7) 7
bevacizumab (7) 7
cancer (7) 7
cohort studies (7) 7
medicine, general & internal (7) 7
patients (7) 7
risk (7) 7
risk factors (7) 7
studies (7) 7
type 2 diabetes (7) 7
antibodies, monoclonal - adverse effects (6) 6
cardiac & cardiovascular systems (6) 6
macular degeneration (6) 6
multidisciplinary sciences (6) 6
older people (6) 6
physiological aspects (6) 6
quality of life (6) 6
quality-of-life (6) 6
ranibizumab (6) 6
tumors (6) 6
cardiovascular diseases (5) 5
catalogs (5) 5
child (5) 5
comparative analysis (5) 5
exposiciones (5) 5
expositions (5) 5
health status (5) 5
heart failure (5) 5
infant (5) 5
obesity (5) 5
population (5) 5
prospective studies (5) 5
public health (5) 5
age (4) 4
animals (4) 4
antibodies, monoclonal - administration & dosage (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
architecture (4) 4
art collections (4) 4
art, modern (4) 4
body mass index (4) 4
cardiac patients (4) 4
cardiovascular (4) 4
cardiovascular disease (4) 4
catalogues d'exposition (4) 4
child, preschool (4) 4
confidence intervals (4) 4
cross-sectional studies (4) 4
diagnosis (4) 4
disease progression (4) 4
diseases (4) 4
epidemiology (4) 4
exercise (4) 4
eye (4) 4
eye diseases (4) 4
fluorescein angiography (4) 4
gene expression (4) 4
history (4) 4
houston (4) 4
immunotherapy (4) 4
in infancy & childhood (4) 4
infant, newborn (4) 4
ligands (4) 4
medical colleges (4) 4
metastasis (4) 4
methods (4) 4
odds ratio (4) 4
pathology (4) 4
prevalence (4) 4
prevention (4) 4
research article (4) 4
research design (4) 4
surveys and questionnaires (4) 4
therapy (4) 4
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (18) 18
Gerstein Science - Stacks (9) 9
Royal Ontario Museum - Stacks (7) 7
Art - Library use only (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
UTL at Downsview - May be requested (2) 2
UofT at Scarborough - Stacks (2) 2
Art - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
Media Commons - Audio Visual (1) 1
Music - Stacks (1) 1
OISE - Stacks (1) 1
UofT at Mississauga - Oversize (1) 1
UofT at Mississauga - Reference (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (131) 131
Spanish (4) 4
French (1) 1
German (1) 1
Latin (1) 1
Portuguese (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 67 - 76
Journal Article
Nature, ISSN 0028-0836, 11/2014, Volume 515, Issue 7528, pp. 563 - 567
Journal Article
Nature, ISSN 0028-0836, 02/2018, Volume 554, Issue 7693, pp. 544 - 548
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | BLADDER-CANCER | THERAPY | LANDSCAPE | SUBTYPES | UROTHELIAL CARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | ADAPTIVE IMMUNE RESISTANCE | MPDL3280A | CD8-Positive T-Lymphocytes - cytology | Humans | Antibodies, Monoclonal - therapeutic use | Urothelium - pathology | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Immunotherapy | Antibodies - immunology | Antigens, Neoplasm - metabolism | Transforming Growth Factor beta - antagonists & inhibitors | Antigens, Neoplasm - analysis | Disease Models, Animal | Fibroblasts - metabolism | Antibodies - therapeutic use | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - pharmacology | Treatment Outcome | B7-H1 Antigen - immunology | Urologic Neoplasms - immunology | Antibodies - pharmacology | Tumor Microenvironment - immunology | Collagen - metabolism | Phenotype | Animals | B7-H1 Antigen - antagonists & inhibitors | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | CD8-Positive T-Lymphocytes - drug effects | Urothelium - immunology | Mice | Mutation | CD8-Positive T-Lymphocytes - immunology | Urothelium - drug effects | Transforming Growth Factor beta - metabolism | Cohort Studies | Drug Resistance, Neoplasm - drug effects | PD-1 protein | CD8 antigen | Transforming growth factor-a | Antibodies | Parenchyma | Lymphocytes T | Metastasis | Immunity | Metastases | Genotype & phenotype | Signal transduction | Lymphocytes | Cell cycle | Fibroblasts | Growth factors | Urothelial cancer | Phenotypes | Cytokines | Melanoma | Blocking | Gene expression | Patients | Generalized linear models | Signaling | Stromal cells | Medical prognosis | Collagen | PD-L1 protein | Ligands | Determinants | Infiltration | Cancer | Tumors | Apoptosis | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2018, Volume 24, Issue 6, pp. 749 - 757
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib... 
MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | PD-L1 EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-III | SINGLE-ARM | CANCER | CELL BIOLOGY | PATHWAY | SUPPRESSOR-CELLS | NIVOLUMAB | TUMOR-GROWTH | ENDOTHELIAL GROWTH-FACTOR | Sunitinib - pharmacology | Bevacizumab - pharmacology | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Male | Gene Expression Profiling | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Treatment Outcome | Mutation - genetics | Sunitinib - adverse effects | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Development and progression | Dosage and administration | Angiogenesis inhibitors | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Cell survival | Inflammation | Gene expression | Molecular chains | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Immune checkpoint | Immunotherapy | γ-Interferon | PD-L1 protein | Biomarkers | Bioindicators | Vascular endothelial growth factor | Clear cell-type renal cell carcinoma | Index Medicus
Journal Article